Quince Therapeutics holds special shareholder meeting

• Quince Therapeutics held a special shareholder meeting on Oct. 6, 2026.
• Shareholders authorized issuance of common shares tied to conversion of Series C Non-Voting Convertible Preferred Stock and related warrants or options.
• Investors also cleared a separate share issuance tied to Series C Preferred Stock and related warrants issued in a private placement.
• An amendment raising authorized common shares to 275,000,000 from 250,000,000 was adopted and filed effective Oct. 6, 2026.
• Stockholders adopted the 2026 equity incentive plan and the 2026 employee stock purchase plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-415730), on October 06, 2026, and is solely responsible for the information contained therein.